Abstract
Objective Vaccination reduces the risk of acute COVID-19 in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5-17 years.
Methods This retrospective cohort study used data from 17 health systems in the RECOVER PCORnet electronic health record (EHR) Program for visits between vaccine availability, and October 29, 2022. Conditional logistic regression was used to estimate VE against long COVID with matching on age group (5-11, 12-17) and time period and adjustment for sex, ethnicity, health system, comorbidity burden, and pre-exposure health care utilization. We examined both probable (symptom-based) and diagnosed long COVID in the year following vaccination.
Results The vaccination rate was 56% in the cohort of 1,037,936 children. The incidence of probable long COVID was 4.5% among patients with COVID-19, while diagnosed long COVID was 0.7%. Adjusted vaccine effectiveness within 12 months was 35.4% (95 CI 24.5 – 44.5) against probable long COVID and 41.7% (15.0 – 60.0) against diagnosed long COVID. VE was higher for adolescents 50.3% [36.3 – 61.0]) than children aged 5-11 (23.8% [4.9 – 39.0]). VE was higher at 6 months (61.4% [51.0 – 69.6]) but decreased to 10.6% (–26.8 – 37.0%) at 18-months.
Discussion This large retrospective study shows a moderate protective effect of SARS-CoV-2 vaccination against long COVID. The effect is stronger in adolescents, who have higher risk of long COVID, and wanes over time. Understanding VE mechanism against long COVID requires more study, including EHR sources and prospective data.
Article Summary Vaccination against COVID-19 has a protective effect against long COVID in children and adolescents. The effect wanes over time but remains significant at 12 months.
What’s Known on This Subject Vaccines reduce the risk and severity of COVID-19 in children. There is evidence for reduced long COVID risk in adults who are vaccinated, but little information about similar effects for children and adolescents, who have distinct forms of long COVID.
What This Study Adds Using electronic health records from US health systems, we examined large cohorts of vaccinated and unvaccinated patients <18 years old and show that vaccination against COVID-19 is associated with reduced risk of long COVID for at least 12 months.
Contributors’ Statement Drs. Hanieh Razzaghi and Charles Bailey conceptualized and designed the study, supervised analyses, drafted the initial manuscript, and critically reviewed and revised the manuscript.
Drs. Christopher Forrest and Yong Chen designed the study and critically reviewed and revised the manuscript.
Ms. Kathryn Hirabayashi, Ms. Andrea Allen, and Dr. Qiong Wu conducted analyses, and critically reviewed and revised the manuscript.
Drs. Suchitra Rao, H Timothy Bunnell, Elizabeth A. Chrischilles, Lindsay G. Cowell, Mollie R. Cummins, David A. Hanauer, Benjamin D. Horne, Carol R. Horowitz, Ravi Jhaveri, Susan Kim, Aaron Mishkin, Jennifer A. Muszynski, Susanna Nagie, Nathan M. Pajor, Anuradha Paranjape, Hayden T. Schwenk, Marion R. Sills, Yacob G. Tedla, David A. Williams, and Ms. Miranda Higginbotham critically reviewed and revised the manuscript.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Authorship statement Authorship has been determined according to ICMJE recommendations.
Competing Interest Statement
Dr. Mollie Cummins is employed by Doxy.me Inc., a commercial telemedicine platform provider. Dr. Benjamin Horne is a member of the advisory boards of Opsis Health and Lab Me Analytics, and a consultant to Pfizer (regarding clinical risk scores; funds paid to Intermountain). Dr. Susanna Naggie reports research grants from Gilead Sciences and AbbVie, scientific advisor/stock options from Vir Biotechnologies, consulting with no financial payment from Pardes Biosciences and Silverback Therapeutics, DSMB fees from Personal Health Insights, Inc, event adjudication committee fees from BMS/PRA outside the submitted work. Dr. Mishkin receives Grant support from Pfizer paid directly to Institution Advisory Board for Takeda. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society. Dr. Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. The remaining authors have no disclosures.
Funding Statement
This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Biomedical Research Alliance of New York waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: Dr. Mollie Cummins is employed by Doxy.me Inc., a commercial telemedicine platform provider. Dr. Benjamin Horne is a member of the advisory boards of Opsis Health and Lab Me Analytics, and a consultant to Pfizer (regarding clinical risk scores; funds paid to Intermountain). Dr. Susanna Naggie reports research grants from Gilead Sciences and AbbVie, scientific advisor/stock options from Vir Biotechnologies, consulting with no financial payment from Pardes Biosciences and Silverback Therapeutics, DSMB fees from Personal Health Insights, Inc, event adjudication committee fees from BMS/PRA outside the submitted work. Dr. Mishkin receives Grant support from Pfizer paid directly to Institution Advisory Board for Takeda. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society. Dr. Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. The remaining authors have no disclosures
Funding/Support: This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research
Disclaimer: The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH
Abbreviations: PCR – polymerase chain reaction; EHR – electronic health record; CI – 95% confidence intervals; ICD-10-CM – International Classification of Diseases, version 10, clinical modification; PMCA – Pediatric Medical Complexity Algorithm; US – United States of America; VE – vaccine effectiveness; VIS – vaccine information system
This revised version of the manuscript includes minor formatting changes and an accurate author list.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
